Evaluation of Women's Experience With EVRA (Norelgestromin + Ethinyl Estradiol) Transdermal Contraceptive Patch Compared With Previous Methods of Contraception.

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of the study is to evaluate user experience with the EVRA® Contraceptive Transdermal Patch; specifically, user satisfaction with the EVRA® Patch, and if applicable, user preference of the EVRA® Patch compared with the previous method of contraception. The study also evaluates contraceptive efficacy, safety and user compliance.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Janssen Pharmaceutica N.V., Belgium
• Treatments: Contraceptive Agents; Estradiol; Estradiol 17 beta-cypionate; Estradiol 3-benzoate; Estradiol valerate; Ethinyl Estradiol; Norelgestromin; Norgestrel; Polyestradiol phosphate

Criteria

Inclusion Criteria:

• Regular menstrual cycles

• sexually active and at risk of pregnancy

• nonpregnant

• normal Pap smear

Exclusion Criteria:

• Presently have or at risk of venous thrombosis or arterial thrombosis

• migraines with focal aura

• severe hypertension

• diabetes mellitus

• hereditary dyslipoproteinemia

• carcinoma of breast, endometrium or other estrogen-dependent neoplasia

• substance abuse

• skin conditions

• concurrent use of hormone-containing medication

• smoking women over 35 years of age.